Edwards Lifesciences price target raised to $100 from $95 at Stifel

Stifel raised the firm’s price target on Edwards Lifesciences (EW) to $100 from $95 and keeps a Buy rating on the shares after having attended Edwards’ annual investor day meeting. The firm, which says initial 2026 guidance “looks like a solid starting point,” left the meeting feeling positive about Edwards’ 2026 outlook and long-term set-up, the analyst tells investors.